Effects of mitotane on gene expression in the adrenocortical cell line NCI-H295R: A microarray study

Pharmacogenomics

Volumn 13, Issue 12, 2012, Pages 1351-1361

  Zsippai, Adrienn ^a   Szabó, Diana Rita ^a   Tömböl, Zsófia ^a   Szabó, Peter M ^a   Éder, Katalin ^a   Pállinger, Éva ^a   Gaillard, Rolf C ^b   Patócs, Attila ^c   Tóth, Sára ^a   Falus, András ^a   Rácz, Károly ^a   Igaz, Peter ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

adrenocortical cancer; gene expression; microarray; mitotane; steroid biosynthesis

Indexed keywords

GROWTH DIFFERENTIATION FACTOR 15; MITOTANE;

ADRENAL CORTEX CARCINOMA; ALDH1L2 GENE; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYP21A2 GENE; GDF15 GENE; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; HSD3B1 GENE; HSD3B2 GENE; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; SERPINE2 GENE; STEROIDOGENESIS; TRIB3 GENE;

ADRENAL CORTEX; ADRENAL CORTEX NEOPLASMS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL LINE, TUMOR; CELL SURVIVAL; GENE EXPRESSION; HORMONES; HUMANS; MICROARRAY ANALYSIS; MITOTANE; RNA, MESSENGER;

EID: 84866340964     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.116     Document Type: Article

References (50)

1. Hahner S, Fassnacht M. Mitotane for adrenocortical carcinoma treatment. Curr. Opin. Invest. Drugs 6(4), 386-394 (2005 (Pubitemid 40561415)
2. Maluf DF, de Oliveira BH, Lalli E. Therapy of adrenocortical cancer: Present and future. Am. J. Cancer Res. 1(2), 222-232 (2011
3. Langer P, Bartsch D, Moebius E, Rothmund M, Nies C. Adrenocortical carcinoma - our experience with 11 cases. Langenbecks Arch. Surg. 385(6), 393-397 (2000
4. Berruti A, Ferrero A, Sperone P et al. Emerging drugs for adrenocortical carcinoma. Expert Opin. Emerg. Drugs 13(3), 497-509 (2008
5. Libè R, Fratticci A, Bertherat J. Adrenocortical cancer: Pathophysiology and clinical management. Endocr. Relat. Cancer 14(1), 13-28 (2007 (Pubitemid 47521719)
6. Powers JM, Hennigar GR, Grooms G, Nichols J. Adrenal cortical degeneration and regeneration following administration of DDD. Am. J. Pathol., 75(1), 181-194 (1974
7. Cai W, Counsell RE, Djanegara T, Schteingart DE, Sinsheimer JE, Wotring LL. Metabolic activation and binding of mitotane in adrenal cortex homogenates. J. Pharm. Sci. 84(2), 134-138 (1995
8. Kurokohchi K, Nishioka M, Ichikawa Y. Inhibition mechanism of reconstituted cytochrome P-450scc-linked monooxygenase system by antimycotic reagents and other inhibitors. J. Steroid Biochem. Mol. Biol. 42(3-4), 287-292 (1992
9. Brown RD, Nicholson WE, Chick WT, Strott CA. Effect of o,ṕ-DDD on human adrenal steroid 11b-hydroxylation activity. J. Clin. Endocrinol. Metab. 36(4), 730-733 (1973
10. Touitou Y, Bogdan A, Auzeby A, Dommergues JP. Glucocorticoid and mineralocorticoid pathways in two adrenocortical carcinomas: Comparison of the effects of o,ṕ- dichlorodiphenyldichloroethane, aminoglutethimide and 2-p-aminophenyl-2- phenylethylamine in vitro. J. Endocrinol. 82(1), 87-94 (1979 (Pubitemid 9238412)
11. Robinson BG, Hales IB, Henniker AJ et al. The effect of o,ṕ-DDD on adrenal replacement therapy requirements. Clin. Endocrinol. (Oxf.) 27(4), 437-444 (1987 (Pubitemid 17148599)
12. Igaz P, Tömböl Z, Szabó PM, Likó I, Rácz K. Steroid biosynthesis inhibitors in the therapy of hypercortisolism: Theory and practice. Curr. Med. Chem. 15(26), 2734-2747 (2008
13. Asp V, Cantillana T, Bergman A, Brandt I. Chiral effects in adrenocorticolytic action of o,ṕ-DDD (mitotane) in human adrenal cells. Xenobiotica 40(3), 177-183 (2010
14. Cai W, Benitez R, Counsell RE et al. Bovine adrenal cortex transformations of mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2- dichloroethane; o,ṕ-DDD] and its p,ṕ- and m,ṕ-isomers. Biochem. Pharmacol. 49(10), 1483-1489 (1995
15. Benecke R, Keller E, Vetter B, de Zeeuw RA. Plasma level monitoring of mitotane (o,ṕ-DDD) and its metabolite (o,ṕ-DDE) during long-term treatment of Cushing's disease with low doses. Eur. J. Clin. Pharmacol. 41(3), 259-261 (1991
16. Haak HR, Hermans J, van de Velde CJ et al. Optimal treatment of adrenocortical carcinoma with mitotane: Results in a consecutive series of 96 patients. Br. J. Cancer 69, 947-951(1994 (Pubitemid 24140681)
17. Goon PK, Boos CJ, Stonelake PS, Blann AD, Lip GY. Detection and quantification of mature circulating endothelial cells using flow cytometry and immunomagnetic beads: A methodological comparison. Thromb. Haemost. 96(1), 45-52 (2006 (Pubitemid 44160870)
18. Subramanian A, Tamayo P, Mootha VK et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102(43), 15545-15550 (2005 (Pubitemid 41528093)
19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-d d C (T)) method. Methods 25(4), 402-408 (2001 (Pubitemid 34164012)
20. Sylvester PW. Optimization of the tetrazolium dye (MTT) colorimetric assay for cellular growth and viability. Methods Mol. Biol. 716, 157-168 (2011
21. Krajewski S, Kurz J, Wendel HP, Straub A. Flow cytometry analysis of porcine platelets: Optimized methods for best results. Platelets 23(5), 386-394 (2011
22. Stigliano A, Cerquetti L, Borro M et al. Modulation of proteomic profile in H295R adrenocortical cell line induced by mitotane. Endocr. Relat. Cancer 15(1), 1-10 (2008 (Pubitemid 351449723)
23. Ohlsson A, Ullerås E, Cedergreen N, Oskarsson A. Mixture effects of dietary flavonoids on steroid hormone synthesis in the human adrenocortical H295R cell line. Food Chem. Toxicol. 48(11), 3194-3200 (2010
24. Rainey WE, Saner K, Schimmer BP. Adrenocortical cell lines. Mol. Cell. Endocrinol. 228(1-2), 23-38 (2004 (Pubitemid 39482517)
25. Lindhe O, Skogseid B. Mitotane effects in a H295R xenograft model of adjuvant treatment of adrenocortical cancer. Horm. Metab. Res. 42(10), 725-730 (2010
26. Cerquetti L, Sampaoli C, Amendola D et al. Mitotane sensitizes adrenocortical cancer cells to ionizing radiations by involvement of the cyclin B1/CDK complex in G2 arrest and mismatch repair enzymes modulation. Int. J. Oncol. 37(2), 493-501 (2010
27. Luconi M, Poli G, Mangoni M et al. Effects and kinetics of mitotane in in vitro and in vivo models of adrenocortical carcinoma. Presented at: European Congress of Endocrinology 2011. Rotterdam, Netherlands, 30 April-4 May 2011.
28. Cerquetti L, Bucci B, Marchese R et al. Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines. Endocr. Relat. Cancer 15(2), 623-634 (2008 (Pubitemid 351880848)
29. Cheng WC, Chang CW, Chen CR et al. Identification of reference genes across physiological states for qRT-PCR through microarray meta-analysis. PLoS ONE 6(2), E17347 (2011
30. Nader N, Raverot G, Emptoz-Bonneton A et al. Mitotane has an estrogenic effect on sex hormone-binding globulin andcorticosteroid binding globulin in humans. J. Clin. Endocrinol. Metab. 91(6), 2165-2170 (2006 (Pubitemid 43855000)
31. Schteingart DE, Sinsheimer JE, Counsell RE et al. Comparison of adrenalytic activity of mitotane and a methylated homolog on normal adrenal cortex and adrenal cortical carcinoma. Cancer Chemother. Pharm. 31, 459-466 (1993 (Pubitemid 23093318)
32. Yatomi M, Takiguchi Y, Asaka-Amano Y et al. Altered gene expression by cisplatin in a human squamous cell lung carcinoma cell line. Anticancer Res. 27, 3235-3243 (2007 (Pubitemid 47607547)
33. Carminati PO, Mello SS, Fachin AL et al. Alterations in gene expression profiles correlated with cisplatin cytotoxicity in the glioma U343 cell line. Genet. Mol. Biol. 33(1), 159-168 (2010
34. Hao H, Dong YB, Bowling MT, Zhou HS, McMasters KM. Alteration of gene expression in melanoma cells following combined treatment with E2F-1 and doxorubicin. Anticancer Res. 26, 1947-1956 (2006 (Pubitemid 43989454)
35. Bruheim S, Xi Y, Ju J, Fodstad O. Gene expression profiles classify human osteosarcoma xenografts according to sensitivity to doxorubicin, cisplatin, and ifosfamide. Clin. Cancer. Res. 15(23), 7161-7169 (2009
36. Simard J, Ricketts ML, Gingras S, Soucy P, Feltus FA, Melner MH. Molecular biology of the 3ß-hydroxysteroid dehydrogenase/?5-?4 isomerase gene family. Endocr. Rev. 26(4), 525-582 (2005 (Pubitemid 41014265)
37. Krupenko NI, Dubard ME, Strickland KC, Moxley KM, Oleinik NV, Krupenko SA. ALDH1L2 is the mitochondrial homolog of 10-formyltetrahydrofolate dehydrogenase. J. Biol. Chem. 285(30), 23056-23063 (2010
38. Candia BJ, Hines WC, Heaphy CM, Griffith JK, Orlando RA. Protease nexin-1 expression is altered in human breast cancer. Cancer Cell. Int. 6, 16 (2006
39. Buchholz M, Biebl A, Neesse A et al. SERPINE2 (protease nexin I) promotes extracellular matrix production and local invasion of pancreatic tumors in vivo. Cancer Res. 63(16), 4945-4951 (2003 (Pubitemid 37022630)
40. Thelin-Järnum S, Lassen C, Panagopoulos I, Mandahl N, Aman P. Identification of genes differentially expressed in TLS-HOP carrying myxoid liposarcomas. Int. J. Cancer 83(1), 30-33 (1999 (Pubitemid 29409472)
41. Gao S, Krogdahl A, Sørensen JA, Kousted TM, Dabelsteen E, Andreasen PA. Overexpression of protease nexin-1 mRNA and protein in oral squamous cell carcinomas. Oral. Oncol. 44(3), 309-313 (2008 (Pubitemid 351249194)
42. Bergeron S, Lemieux E, Durand V et al. The serine protease inhibitor serpinE2 is a novel target of ERK signaling involved in human colorectal tumorigenesis. Mol. Cancer 9, 271 (2010
43. Fernandez-Ravier GG, Weng J et al. Candidate diagnostic markers ad tumor suppressor genes for adrenocortical carcinoma by expression profile of genes on chromosome 11q13. World J. Surg. 32(5), 873-881 (2008
44. Staff AC, Bock AJ, Becker C, Kempf T, Wollert KC, Davidson B. Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer. Gynecol. Oncol. 118(3), 237-243 (2010
45. Bock AJ, Stavnes HT, Kempf T et al. Expression and clinical role of growth differentiation factor-15 in ovarian carcinoma effusions. Int. J. Gynecol. Cancer 20(9), 1448-1455 (2010
46. Ohoka N, Yoshii S, Hattori T, Onozaki K, Hayashi H. TRB3 a novel ER stress-inducible gene, is induced via ATF4-CHOP pathway and is involved in cell death. EMBO J. 24, 1243-1255 (2005 (Pubitemid 40516607)
47. Hua F, Mu R, Liu J et al. TRB3 interacts with SMAD3 promoting tumor cell migration and invasion. J. Cell Sci. 124(19), 3235-3246 (2011
48. Xu J, Lv S, Qin Y et al. TRB3 interacts with CtIP and is overexpressed in certain cancers. Biochim. Biophys. Acta 1770(2), 273-278 (2007 (Pubitemid 46019808)
49. Wennemers M, Bussink J, Scheijen B et al. Tribbles homolog 3 denotes a poor prognosis in breast cancer and is involved in hypoxia response. Breast Cancer Res. 13, R82 (2011
50. Miyoshi N, Ishii H, Mimori K et al. Abnormal expression of TRIB3 in colorectal cancer: A novel marker for prognosis. Br. J. Cancer. 101(10), 1664-1670 (2009